drugset / Trial / NCT02004587

Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers

NCT02004587

Phase 1 Completed 28 enrolled LG Life Sciences
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The trial will investigate the influence of hepatic function on the PK of gemigliptin. In an additional treatment period, the PK and safety of multiple dosing of gemigliptin in healthy White subjects will be investigated.

Timeline

Start
2013-09
Primary completion
2014-05
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemigliptin Small molecule Oral

Indications

No indication recorded.